Genmab — December 2012
-
“Vi gør fortsat gode fremskridt i vores samarbejde med Lundbeck og har nu nået denne milestone vedrørende in vitro proof-of-concept for det tredje target i programmet,” siger Jan van de Winkel, ph.d., Chief Executive Officer hos Genmab, i meddelelsen.
Nyheden får ikke 'væsentlig indflydelse' på årets resultater, fremgår det.
-
vi er nok tæt på at være i toprange i forventningerne nu
-
så nu skal de lige holde på hestene hvis ikke de skal løbe panden lige ind i endnu en opjustering
-
send dem på tidlig juleferie jan
-
Our revenue consists primarily of non-cash amortization of deferred revenue totaling approximately DKK
250 million and royalties on sales of Arzerra, which are now expected to be in the range of DKK 105 –
115 million an increase of DKK 15 million compared to the previous guidance of DKK 90 – 100 million. -
af de 450-475 er de 355-365 låst af
-
så har vi fået en del milestones også
-
og altså omkring 20 mill i denne uge....
-
humlen er lidt om de har indregnet milestones i deres revenue forventninger....
-
deres range er 20 mill, så den ligger lidt og tipper
-
jeg har spurgt rachel
-
The two milestones announced did not have a material impact on our financial guidance, so that probably answers your question!
-
Respect for the speed
-
@gen.co kun MLI der committer i den p.t. news or no news
-
lukkede i day high næsten 100K omsat. Det er derop vi skal vær volume mæssigt hverdag
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind